<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03354208</url>
  </required_header>
  <id_info>
    <org_study_id>AAMBI I</org_study_id>
    <nct_id>NCT03354208</nct_id>
  </id_info>
  <brief_title>Asphyxia Associated Metabolite Biomarker Investigation (AAMBI)</brief_title>
  <acronym>AAMBI</acronym>
  <official_title>Verification of Biomarkers to Examine Neonatal Asphyxia Induced Hypoxic-ischemic Encephalopathy. A Prospective Multicenter Observational Study for Development of a Diagnostic Test</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Life Science Inkubator</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cukurova University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Children’s Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Life Science Inkubator</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Verification of biomarkers in a human population for their ability to diagnose the severity
      of neonatal asphyxia. These biomarkers linked to asphyxia have been identified in animal
      studies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the study is to verify the application of combinations of several laboratory
      parameters in early postnatal blood samples, for identification of infants, who will suffer
      from early abnormal neonatal neurological outcome, in a population at risk.

      The population at risk is defined as term and late preterm (&gt;36 weeks of gestation) human
      infants following perinatal hypoxia-ischemia with or without postnatal resuscitation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2016</start_date>
  <completion_date type="Actual">December 27, 2017</completion_date>
  <primary_completion_date type="Actual">December 27, 2017</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>14 Days</target_duration>
  <primary_outcome>
    <measure>abnormal short-term outcome (NE)</measure>
    <time_frame>14 days for clinical diagnosis</time_frame>
    <description>All patients are classified as abnormal short-term outcome (neonatal encephalopathy, NE) or normal short term outcome (no encephalopathy) by using clinical data, particularly Thompson score. For Group 1 and group 2 patients outcome classification will be additionally confirmed by using cranial ultrasound or MRI (including severe ischemia based on DWI or thalamic or cerebellar bleeding or arterial infarction or IVH&gt;2° according to Papile, thalamic ischemia or severe cerebral edema) or seizure activity or burst suppression on aEEG or persistingly abnormal aEEG background pattern after complete rewarming.
Bloodplasma samples will be analysed by a metabolomics approach using the p180-kit (Biocrates, Innsbruck, Austria). Metabolite concentrations or combinations thereof will be compared to the outcome described above in order to identify the most suitable metabolites to be used for early detection of NE in newborn infants.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">128</enrollment>
  <condition>Asphyxia Neonatorum</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <description>patients with hypoxic-ischemic encephalopathy (HIE) receiving hypothermia therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <description>patients with suspected HIE, non-confirmed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <description>healthy, retrospectively classified as such</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood sampling</intervention_name>
    <description>small volume blood sampling, according to local laws, is not categorized as intervention (observational study)</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Infants at risk for perinatal hypoxic-ischemic brain injury
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Group 1: inclusion criteria fulfilled for hypothermia treatment Group 2: Infants with
        suspected perinatal brain injury due to one of the followings

          -  Perinatal hypoxia-ischemia (defined as a perinatal acidosis indicated by a pH≤7.10 or
             a base excess ≤-12mmol/l in umbilical cord blood or early postnatal blood collected at
             &lt;90min of age (outborn patients)

          -  5min APGAR-score ≤ 5

          -  Need for resuscitation after birth for &gt;1 min. after birth, positive pressure
             respiratory support with face mask or endotracheal tube, or cardiac compressions Group
             3: UApH &gt;7,25, and adaptation disorder of the newborn and need of postnatal clinical
             surveillance

        Exclusion Criteria:

        gestational age &lt; 36 weeks

          -  age at time of screening &gt;2,5h

          -  congenital malformation

          -  missing or invalid informed parental consent

          -  unsuccessful resuscitation

          -  infant considered not-viable

          -  decision for palliative care only
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>2 Hours</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ron Meyer</last_name>
    <role>Study Director</role>
    <affiliation>Life Science Inkubator Betriebs GmbH &amp; Co. KG</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cukurova University</name>
      <address>
        <city>Adana</city>
        <zip>01330</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Firat</name>
      <address>
        <city>Elazığ</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Özel Güngören Hastanesi</name>
      <address>
        <city>İstanbul</city>
        <zip>34164</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mersin University School of Medicine</name>
      <address>
        <city>Mersin</city>
        <zip>33343</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2017</study_first_submitted>
  <study_first_submitted_qc>November 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 27, 2017</study_first_posted>
  <last_update_submitted>March 15, 2018</last_update_submitted>
  <last_update_submitted_qc>March 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>biomarkers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoxia-Ischemia, Brain</mesh_term>
    <mesh_term>Asphyxia</mesh_term>
    <mesh_term>Asphyxia Neonatorum</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

